NSPR

+ Watchlist + Portfolio

InspireMD Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.91
52-Week Range: $0.63 – $2.57
Market Cap: $42.15M
P/E (TTM): —
EPS (TTM): -0.61
Dividend Yield: —

Advanced Metrics

Price/Book: 0.71
PEG Ratio: —
Return on Equity: -142.60%
Return on Assets: -68.49%
Gross Margin: 28.06%
Operating Margin: -411.36%
Profit Margin: 0.00%
Current Ratio: 5.15
Debt/Equity: 0.07
Total Debt: $3.11M
Free Cash Flow: $-21.12M
Revenue Growth: 122.20%
Earnings Growth: —
Enterprise Value: $7.55M

NSPR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$5.17M	$6.21M	$7.01M	$8.98M
Cost of Revenue	$4.05M	$4.40M	$5.50M	$6.33M
Gross Profit	$1.12M	$1.81M	$1.51M	$2.65M
Research & Development	$7.81M	$7.98M	$13.63M	$15.00M
Selling, General & Admin	$12.02M	$14.97M	$21.38M	$37.26M
Operating Expenses	$19.83M	$22.95M	$35.01M	$52.26M
Operating Income	-$18.71M	-$21.14M	-$33.50M	-$49.61M
EBITDA	-$18.52M	-$20.91M	-$33.22M	-$49.14M
Pretax Income	-$18.46M	-$19.85M	-$31.95M	-$48.72M
Income Tax	$28.00K	$65.00K	$59.00K	$63.00K
Net Income	-$18.49M	-$19.92M	-$32.01M	-$48.79M
Diluted EPS	-2.35	-0.82	-0.76	-0.76
Diluted Shares	7.87M	24.27M	41.93M	64.33M

NSPR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.63M	$9.64M	$18.92M	$8.94M
Receivables	$1.25M	$2.45M	$2.25M	$2.57M
Inventory	$1.62M	$2.11M	$2.57M	$3.40M
Current Assets	$21.33M	$44.16M	$40.52M	$61.47M
Total Assets	$24.65M	$47.64M	$46.81M	$69.40M
Current Liabilities	$5.07M	$6.02M	$7.68M	$10.71M
Total Debt	$1.61M	$1.59M	$2.34M	$3.29M
Total Liabilities	$7.26M	$8.14M	$10.72M	$14.20M
Retained Earnings	-$201.59M	-$221.50M	-$253.51M	-$302.29M
Shareholders' Equity	$17.39M	$39.50M	$36.09M	$55.20M
Working Capital	$16.26M	$38.14M	$32.84M	$50.76M

NSPR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.54M	-$16.38M	-$21.87M	-$35.10M
Capital Expenditure	-$473.00K	-$381.00K	-$1.40M	-$1.66M
Free Cash Flow	-$16.02M	-$16.76M	-$23.27M	-$36.77M
Depreciation & Amortisation	$188.00K	$232.00K	$280.00K	$476.00K
Stock-Based Compensation	$2.35M	$4.49M	$10.14M	$12.33M
Investing Cash Flow	$8.44M	-$16.09M	$12.64M	-$30.56M
Financing Cash Flow	-$140.00K	$37.53M	$18.45M	$55.57M
Net Change in Cash	-$7.24M	$5.07M	$9.22M	-$10.09M

NSPR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$1.53M	$1.78M	$2.52M	$3.15M	$3.40M
Cost of Revenue	$1.24M	$1.47M	$1.66M	$1.97M	$2.71M
Gross Profit	$292.00K	$313.00K	$864.00K	$1.18M	$687.00K
Research & Development	$4.06M	$3.83M	$3.63M	$3.48M	$4.76M
Selling, General & Admin	$7.69M	$9.50M	$10.28M	$9.79M	$9.90M
Operating Expenses	$11.75M	$13.33M	$13.91M	$13.26M	$14.66M
Operating Income	-$11.46M	-$13.02M	-$13.05M	-$12.08M	-$13.98M
EBITDA	-$11.36M	-$12.91M	-$12.92M	-$11.94M	-$13.83M
Pretax Income	-$11.17M	-$13.15M	-$12.71M	-$11.70M	-$13.69M
Net Income	-$11.17M	-$13.15M	-$12.71M	-$11.76M	-$13.69M
Diluted EPS	-0.22	-0.26	-0.17	-0.14	-0.16
Diluted Shares	49.99M	51.00M	73.47M	82.37M	83.80M

NSPR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$12.38M	$11.51M	$63.40M	$8.94M	$11.36M
Receivables	$2.34M	$2.09M	$2.44M	$2.57M	$2.79M
Inventory	$2.82M	$3.05M	$3.61M	$3.40M	$3.04M
Current Assets	$32.14M	$25.46M	$70.39M	$61.47M	$48.59M
Total Assets	$38.67M	$33.34M	$78.47M	$69.40M	$56.47M
Current Liabilities	$7.37M	$9.07M	$10.82M	$10.71M	$9.44M
Total Debt	$2.32M	$3.42M	$3.37M	$3.29M	$3.11M
Total Liabilities	$10.33M	$13.10M	$14.36M	$14.20M	$12.85M
Retained Earnings	-$264.67M	-$277.82M	-$290.53M	-$302.29M	-$315.98M
Shareholders' Equity	$28.34M	$20.24M	$64.11M	$55.20M	$43.62M
Working Capital	$24.78M	$16.39M	$59.58M	$50.76M	$39.15M

NSPR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.79M	-$8.33M	-$8.63M	-$9.35M	-$12.34M
Capital Expenditure	-$359.00K	-$576.00K	-$329.00K	-$398.00K	-$194.00K
Free Cash Flow	-$9.15M	-$8.91M	-$8.96M	-$9.74M	-$12.53M
Depreciation & Amortisation	$98.00K	$107.00K	$128.00K	$143.00K	$149.00K
Stock-Based Compensation	$2.73M	$3.21M	$3.54M	$2.85M	$2.10M
Investing Cash Flow	$1.70M	$5.32M	$7.55M	-$45.13M	$14.78M
Financing Cash Flow	$506.00K	$2.14M	$52.93M	$0.00	$0.00
Net Change in Cash	-$6.58M	-$874.00K	$51.84M	-$54.48M	$2.44M

Market Snapshot

About

InspireMD Inc. develops and manufactures stent systems with MicroNet mesh technology for treating vascular disease. The company focuses on carotid artery stenting and peripheral vascular interventions where embolic protection is critical. InspireMD markets its CGuard stent system designed to reduce stroke risk during carotid procedures by preventing plaque debris from dislodging.